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Abstract
Background: Health-related quality of life (HRQOL) has been increasingly emphasized in cancer patients. There are no 
reports comparing baseline HRQOL of different subgroups of glioma patients prior to surgery.
Methods: HRQOL assessments by the standard Chinese version of the European Organization for Research and 
Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30, version 3.0), the Mini-Mental State 
Examination and Karnofsky Performance Status were obtained from glioma patients prior to surgery.
Results: Ninety-two pathologically confirmed glioma patients were recruited. There were 84.8% patients with 
emotional impairment, 75% with social and cognitive impairment, 70.7% with physical impairment, and 50% with role 
impairment. Eighty-two percent of patients reported fatigue symptoms, 72.8% reported pain, 50% reported appetite 
loss, 39.1% reported insomnia, and 36.9% reported nausea/vomiting, whereas other symptoms (dyspnea, diarrhea, 
constipation) in the QLQ-C30 were reported by fewer than 30% of patients. Fatigue and pain symptoms and all 
"functioning" scales were strongly correlated with global health status/quality of life (QoL). Fatigue was strongly related 
to all functioning scales, pain, appetite loss, and global health status/QoL. No difference in baseline HRQOL prior to 
surgery was reported between females and males, among different lesion locations, or between normal- and 
abnormal-cognition subgroups of glioma patients. Age, KPS, WHO grade, and tumor recurrence significantly affected 
HRQOL in glioma patients.
Conclusions: These data provided the baseline HRQOL in glioma patients prior to surgery in China. Most pre-surgery 
glioma patients indicated emotional, social, cognitive, physical, and role impairment. Fatigue, pain, appetite loss, 
insomnia, and nausea/vomiting were common in these patients. The fatigue and pain symptoms and all types of 
functioning strongly affected global health status/QoL. Old age, worse performance status, WHO grade IV and tumor 
recurrence had deleterious effects on HRQOL.
Background
Cancers of the brain and nervous system account for
189,000 new cases and 142,000 deaths annually (1.7% of
new cancers and 2.1% of cancer deaths), although such
incidences are probably considerably underestimated
because of the lack of sophisticated diagnostic technology
[1]. Gliomas are the most common primary central ner-
vous system (CNS) tumors; they account for over 40% of
CNS tumors and 78% of CNS malignancies in adults [2].
Gliomas comprise a variety of histopathologic subtypes
arising from the glial matter surrounding neurons in the
brain, with different prognoses. The median survival is
only 12-15 months for patients with glioblastomas
(GBMs) (WHO grade IV), 2-5 years for patients with ana-
plastic gliomas (WHO grade III) [3] and 4-10 years for
patients with low-grade gliomas (LGG, including WHO
grades I and II) [4-6]. Survival is often limited by tumor
recurrence and progression of LGG to high-grade
gliomas (HGG, including WHO grades III and IV). Fac-
tors influencing survival in these patients include histo-
logic subtype, lesion location, age, KPS and cognitive
function [7,8]. Maximal resection [3,9,10], radiotherapy
[11-13], and chemotherapy [12,13] are reported to be
associated with longer overall survival. There is no con-
* Correspondence: xzhang@fmmu.edu.cn
1 Department of Neurosurgery, Xijing Institute of Clinical Neuroscience, Xijing 
Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, China
† Contributed equally
Full list of author information is available at the end of the articleCheng et al. BMC Cancer 2010, 10:305
http://www.biomedcentral.com/1471-2407/10/305
Page 2 of 8
sensus on the optimal management of patients with
residual LGG and HGG following surgical resection, and
even whether (and to what extent) surgical resection
leads to improvements in patient outcome and survival
has been questioned by some neurologists [14,15]. Dur-
ing recent decades, many studies evaluating new thera-
peutic protocols for cancer patients mainly considered
overall survival and progression-free survival as primary
response measures. It is increasingly recognized that the
choice of therapeutic strategy also should entail careful
consideration of its effects on the quality of life (QoL)
during the remaining survival time. Recent research on
health-related quality of life (HRQOL) of patients with
gliomas has been conducted to evaluate the effects of new
treatments in English-speaking and western European
countries. The European Organization for Research and
Treatment of Cancer (EORTC) developed the Core Qual-
ity of Life Questionnaire (QLQ-C30) [16] for assessing
the HRQOL in cancer patients and the Brain Cancer
Module (BCM) [17] for brain tumor patients. The stan-
dard Chinese version of QLQ-C30 (version 3.0) is, over-
all, a valid instrument to assess HRQOL in Chinese
breast, gynecological, and lung cancer patients [18], and
its reliability and validity in brain tumor patients will be
reported in another paper (unpublished data). To date,
there is no Chinese version of BCM available. Osoba et al.
reported the frequency of self-report symptoms and the
effects of disease burden and neurological dysfunction on
QoL in patients with HGG after surgery but prior to
other adjuvant therapy [19,20]. Gustafsson et al. reported
a cross-sectional study on QoL in LGG patients after var-
ious treatments using QLQ-C30 [6]. Findings from a
meta-analysis of individual patient data from EORTC
clinical trials have shown that baseline HRQOL parame-
ters (physical functioning, appetite loss, and pain) post-
surgery but before adjuvant treatment provide significant
prognostic value in various cancer patients [21]. How-
ever, the baseline HRQOL in glioma patients prior to sur-
gery is unknown, especially in China, where there have
been no studies on HRQOL in glioma. The correlation
between demographic and clinical variables and HRQOL
pre-operation also remains elusive.
In this report, we presented baseline HRQOL mea-
sured by the Chinese version of QLQ-C30 (version 3.0)
for glioma patients in China. We analyzed the relation-
ship of demographic and clinical variables with HRQOL
before surgery in glioma patients.
Methods
Subjects
This study was part of a preliminary study on HRQOL in
brain tumor patients in China. The reliability and validity
of the standard Chinese version of EORTC QLQ-C30
(version 3.0) and these patients' HRQOL at baseline (i.e.,
following diagnosis, prior to the start of surgery) will be
reported in another article (unpublished data). In short,
consecutive series of patients with either suspected brain
tumor or diagnosed by CT or MRI were recruited from
July 2008 to December 2008 in the Department of Neuro-
surgery, Xijing Institute of Clinical Neuroscience, Xijing
Hospital, Fourth Military Medical University. The study
was approved by the Institutional Review Board.
Informed consent was obtained from all patients. No
restrictions were placed on patient selection with regard
to histologic type of brain tumors, age, education, cogni-
tive function or performance status. The sample was
restricted to patients who required operation. Post-oper-
ation patients with scheduled radiotherapy or chemo-
therapy were excluded. The standard Chinese version of
QLQ-C30 (version 3.0) was administered following diag-
nosis but prior to operation or re-operation for all eligible
patients. Sociodemographic and clinical data were
recorded before treatment. Scoring of the Chinese ver-
sion of the Mini-Mental State Examination (MMSE) [22]
and Karnofsky Performance Status (KPS) [23] were per-
formed by the doctors or nurses at the time of the first
administration of the QLQ-C30.
The Standard Chinese version of EORTC QLQ-C30 (version 
3.0)
The EORTC QLQ-C30 (version 3.0) is a 30-item ques-
tionnaire composed of multi-item scales and single items
that reflect the multidimensionality of the QoL construct.
It combines five functional scales (physical, role, cogni-
tive, emotional, and social), three symptom scales
(fatigue, pain, and nausea/vomiting), a global health and
QoL scale, six single items assessing additional symptoms
commonly reported by cancer patients (dyspnea, appetite
loss, sleep disturbance, constipation, and diarrhea), as
well as the perceived financial impact of the disease and
treatment [16,18].
Analysis Plan
Only patients with pathologically confirmed glioma were
included in the analysis. Based on MMSE scores, patients
were divided into normal- and abnormal-cognition
groups [22,24]. Briefly, MMSE scores less than 18 in illit-
erate patients, less than 21 in patients with elementary
school education, and less than 25 in patients with more
than high school education were defined as indicating
abnormal cognition. Scoring of the responses to the
QLQ-C30 (version 3.0) was carried out as previously
described [25]. The raw scores for each domain and sin-
gle item were transformed to give a value between 0-100.
For the five functional scales and the global health status/
QoL scale, item responses were recoded so that a higher
score represented a better level of functioning. For the
symptom-oriented scales and items, a higher score corre-Cheng et al. BMC Cancer 2010, 10:305
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sponded to a severe level of symptoms. Differences of at
least 10 points (on a 0-100 scale) were classified as clini-
cally meaningful changes in the mean value of a HRQOL
parameter [26]. Descriptive analysis of HRQOL at the
time of enrollment as measured by QLQ-C30 (version
3.0) was performed. Differences between or within sub-
groups at baseline with respect to each patient character-
istic variable were assessed for all QoL subscales or items
using the Mann Whitney U-test or Kruskal-Wallis test.
Spearman's rank correlation was used to investigate rela-
tionships between the age, KPS, WHO grade and QLQ-
C30 subscales and items. A chi-square test estimated the
constituent ratio of MMSE scores between different age
subgroups. A P value < .05 was considered statistically
significant. Statistical analysis was performed using the
SPSS software package, version 16.0 (SPSS Inc, Chicago,
IL, USA).
Results
Patient Characteristics
In total, 308 brain tumor patients (excluding the patho-
logically confirmed non-cancer patients after surgery)
were enrolled between July 2008 and December 2008, of
whom 92 (29.87%) were pathologically confirmed glioma
patients. Glioma patient characteristics at enrollment are
shown in Table 1. Of the 92 patients evaluated, 57% were
male, and the median age was 42 years (range, 4-76). The
median KPS score was 90, and 21.74% of patients had
abnormal cognition. There were 85.87% supratentorial
tumors, of which 40.5% were located in the left hemi-
sphere. There were 79 patients with newly diagnosed
glioma and 13 patients with recurrent glioma. Table 2
shows the means, standard deviations, median and mode
for the multi-item and single-item measures of the QLQ-
C30. The proportions of all glioma patients with different
scores at baseline prior to surgery in the functioning and
symptom domains are shown in Additional file 1: Table
S1. The full range of possible scores was observed for all
measures except for emotional and cognitive functioning
scales (range, 17-100). Score distributions were negatively
skewed for all the functioning scales (i.e., more patients
scored toward maximum functioning). The median val-
ues of social, emotional, cognitive, physical and role func-
tioning were 66.7, 75.0, 83.3, 86.7 and 91.7, respectively.
Of the patient, 84.8% reported emotional impairment,
75% reported social and cognitive impairment, 70.7%
reported physical impairment, and 50% reported role
impairment. Therefore, the patients reported more and
severer difficulties in emotional and social domains than
in cognitive, physical and role functioning. The median
values were higher for symptoms of fatigue (33.3), pain
(25) and appetite loss (16.7) than for others (0). Eighty-
two percent of patients reported fatigue symptoms, 72.8%
reported pain, 50% reported appetite loss, 39.1% reported
insomnia, and 36.9% reported nausea/vomiting, whereas
other symptoms (dyspnea, diarrhea, and constipation) in
the QLQ-C30 were reported in less than 30% of all
patients. For global health status/QoL, 47.8% patients
reported scores of 50 or less. We further analyzed the
relationships between the item-evaluating scales and sin-
gle items in the QLQ-C30. The results revealed that there
was a significant correlation between global health sta-
tus/QoL and fatigue (rs = -.64, p < .001), physical func-
Table 1: Patient characteristics at enrollment.
Characteristic Number (%)
Gender
Male 57(61.96%)
Female 35(38.04%)
Median age at diagnosis 42 (range, 3-76)
Tumor type
A^ 17(18.47)
OL^ 7(7.61)
OA 9(9.78)
AA^ 11(11.96)
AO^ 2(2.17)
AOA 6(6.52)
GBM 34(36.96)
Other§ 6(6.52)
WHO grade
I3 ( 3 . 2 6 )
II 35(38.04)
III 20(21.74)
IV 34(36.96)
Tumor location
Sub 13(14.13)
Sup 79(85.87)
Frontal lobe 22(27.85)
Temporal lobe 21(26.58)
Parietal lobe 6(7.59)
Occipital lobe 1(1.27)
Multiple lobes 23(29.11)
Other 6(7.60)
Tumor hemisphere
Left 32(40.50)
Right 44(55.70)
Both 3(3.80)
KPS
100 4(4.3)
90 40(43.5)
80 20(21.7)
70 7(7.6)
60 5(5.4)
50 6(6.5)
<50 2(2.2)
Unknown 8(8.7)Cheng et al. BMC Cancer 2010, 10:305
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tioning (rs = .62, p < .001), emotional functioning (rs = .57,
p < .001), role functioning (rs = .57, p < .001), cognitive
functioning (rs = .55, p < .001), pain (rs = -.56, p < .001),
and social functioning (rs = .50, p < .001). In addition to
global health status/QoL, fatigue was significantly corre-
lated with physical functioning (rs = -.738, p < .001), cog-
nitive functioning (rs = -.619, p < .001), role functioning
(rs = -.631 p < .001), pain (rs = .59, p < .001), emotional
functioning (rs = -.527, p < .001), appetite loss (rs = .50, p <
.001) and social functioning (rs = -.457, p < .001).
HRQOL in different subgroup of glioma
There were no differences in baseline score in any QLQ-
C30 subscale or item between female and male patients,
between patients with subtentorial and supratentorial
tumors, between patients with supratentorial tumors in
the left and right hemispheres, among patients with
tumors located in different lobes (frontal, temporal, pari-
etal, multiple lobes), or between patients with normal and
abnormal cognitive function (Additional file 2: Table S2).
The frequencies of dyspnea, diarrhea and constipation
are not shown in Additional file 2: Table S2 because of
their low frequencies. The perceived financial impact of
the disease and treatment is also not included in Addi-
tional file 2: Table S2.
Patients older than 50 reported worse physical (mean
score 72.2 vs. 84.2, p = .014) and role functioning (66.7 vs.
81.6, p = .045), worse global health status/QoL (45.8 vs.
59.4, p = .035), and more insomnia (30.5 vs. 16.4, p = .047)
and constipation (23.8 vs. 8.8, p = .002) symptoms than
those younger than 50 (Additional file 2: Table S2).
Though no differences were apparent on the cognitive
Cognitive function
Normal 71(77.17)
Abnormal 20(21.74)
Unknown 1(1.09)
^ 1 recurrent A, 1 recurrent AA, 1 recurrent AO, 1 recurrent OL.
* 6 recurrent GBM from de novo GBM, 2 secondary GBM.
§1 gangliocytoma WHO grade I, 1 choroid plexus papilloma WHO 
grade I, 1 anaplastic papillary glioneuronal tumor WHO grade III, 2 
ependymoma WHO grade II, 1 recurrent pilocytic astrocytoma WHO 
grade I.
Abbreviations: A: astrocytoma; AA: anaplastic astrocytoma; AOA: 
anaplastic oligoastrocytoma; AO: anaplastic oligodendroglioma; 
GBM: glioblastoma; OA: oligoastrocytoma; OL: oligodendroglioma; 
Sub: subtentorial tumor; Sup: supratentorial tumor.
Table 1: Patient characteristics at enrollment. (Continued)
Table 2: Descriptive statistics of QLQ-C30 in glioma patients.
Items* Mean(SD) Median Mode
Functioning scales^
PF 1-5 79.7(25.1) 86.7 100
RF 6, 7 75.9(30.2) 91.7 100
EF 21-24 75.8(18.6) 75.0 66.7
CF 20, 25 75.0(21.8) 83.3 83.3
SF 26, 27 69.2(26.7) 66.7 66.7
QL 29, 30 54.3(28.7) 58.3 83.3
Symptom scales and/or items§
FA 10, 12, 18 34.1(25.1) 33.3 33.3
NV 14, 15 14.1(24.9) 0.0 0
PA 9, 19 28.3(27.2) 25.0 33.3
DY 8 11.4(19.4) 0.0 0
SL 11 21.7(32.6) 0.0 0
AP 13 23.2(28.3) 16.7 0
CO 16 14.5(25.8) 0.0 0
DI 17 4.0(11.9) 0.0 0
FI 28 44.6(34.7) 33.3 33.3
* Numbers correspond to the item numbers in the questionnaire.
^ Scores range from 0 to 100, with a higher score representing a higher level of functioning.
§Scores range from 0 to 100, with a higher score representing a greater degree of symptoms.
Abbreviations: AP: appetite loss, CF: cognitive functioning; CO: constipation; DI: diarrhea; DY: dyspnea; EF: emotional functioning; FA: fatigue; 
FI: financial difficulties; L: left cerebral hemisphere; NV: nausea/vomiting; PA: pain; QL: global health status; SD: standard deviation; SF: social 
functioning; SL: insomniaCheng et al. BMC Cancer 2010, 10:305
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functional scale, the proportion of patients diagnosed
with abnormal cognition by MMSE was significantly
larger in patients older than 50 than in patients younger
than 50 (abnormal/abnormal cognition 12/22 vs. 8/49, p
= .018). Patients with KPS less than 80 reported worse
physical (51.3 vs. 89, p < .001), role (48.3 vs. 84.9, p <
.001), emotional (65 vs. 80, p = .003), cognitive (55.8 vs.
81.3, p < .001), and social (55.8 vs. 73.7, p = .001) func-
tioning, worse global health status/QoL (29.4 vs. 61.7, p <
.001), and more symptoms of fatigue (60 vs. 25.7, p <
.001), pain (45.8 vs. 22.9, p = .023), insomnia (38.3 vs.
15.6, p = .011) and appetite loss (41.7 vs. 17.7, p = .002)
than those with KPS 80-100 (Additional file 2: Table S2).
Abnormal cognition according to MMSE was associated
with worse KPS compared with normal cognition (75 vs.
82, p = .043).
Patients with WHO grade I tumors were excluded from
the analysis because of their low incidence. There was a
trend that patients with grade IV tumors showed worse
functioning, worse global health status/QoL, and more
symptoms than patients with grade II and III tumors.
Patients with grade IV tumors reported significantly
worse physical (II, III, IV: 83.2, 90, 68.8, respectively; p =
.005), role (80.5, 82.5, 66.2; p = .036), emotional (75.9,
85.8, 70.1; p = .007) and social (76.2, 77.5, 58.3; p = .004)
functioning scores, worse global health status/QoL (58.1,
66.7, 40.6; p = .002,), and more fatigue (31.4, 20.6, 46.4; p
< .001) and pain (28.1, 16.7, 36.8; p = .015) symptoms
(Additional file 2: Table S2). Though no difference in the
aforementioned scales was found between patients with
grade II and III tumors, patients with grade III tumors
reported better function and global health status/QoL
and fewer symptoms than those with grade II tumors.
Correlation analyses showed a significant relationship
between KPS and physical functioning (rs = .61 p < .001),
fatigue (rs = -0.53, p < .001), cognitive functioning (rs = .48
p < .001), role functioning (rs = .45 p < .001) and global
health status/QoL (rs = .42 p < .001) in the QLQ-C30.
Neither age nor WHO grade was related to any scale or
item in the QLQ-C30.
Patients with recurrent glioma, most of which were
recurrent from primary GBMs (6/13), showed worse
physical and social function (71.3 vs. 81.1, p = 0.026 and
52.6 vs. 71.9, p = 0.019, respectively) and worse global
health status/QoL (39.7 vs. 56.7, p = .047) than newly
diagnosed glioma patients (Additional file 2: Table S2).
Discussion
Despite efforts made by neuro-oncologists over the past
several decades, the management of CNS tumors remains
a highly challenging task, with few improvements in long-
term survival, especially in WHO grade III and IV malig-
nancies. Under these circumstances, the HRQOL is a
very important consideration in the overall management
of these patients. Very few data are available about the
HRQOL of patients with glioma prior to surgery, while
more data are available regarding HRQOL in glioma
patients after surgery but before adjuvant therapy, mainly
due to analyses of a large database of patients preparing
to undergo chemo- or radio-therapy [19,20,27-29]. Osoba
et al. [19] analyzed the differences in patients' HRQOL at
recurrence compared to newly diagnosed disease, the fre-
quency and severity of symptoms (symptom burden), and
the effects of tumor histology and baseline HRQOL of
patients with HGG compared to patients with other types
of cancer. In summary, six symptoms (fatigue, uncer-
tainty about the future, motor difficulties, drowsiness,
communication difficulties, and headache) were reported
with a frequency >50% by both GBM and anaplasia astro-
cytoma (AA) patients; visual problems and pain symp-
t o m s  w e r e  a l s o  r e p o r t e d  w i t h  f r e q u e n c i e s  o f  > 5 0 %  b y
patients with recurrent GBM; problems with motor func-
tioning, vision, leg strength, and pain were reported more
frequently by patients with recurrent GBM than by those
with recurrent AA; scores on HRQOL functioning scales
were similar in GBM and AA groups; the QLQ-C30
scores for HGG patients were similar to those with meta-
static cancers and worse than those with localized can-
cers [19]. A cross-sectional study on HRQOL in LGG
patients after various treatments, conducted by Gustafs-
son et al.[6], found that nearly all patients were capable of
self-care, but less than half were able to carry out normal
activities without restriction. The most frequent symp-
toms were fatigue, sleep disturbances and pain, while the
most difficult types of functioning were role, cognitive
and emotional functioning. Of the patients, 45% had
scores indicating low overall QoL, and mental problems
had a stronger impact on QoL than physical ones. A
meta-analysis from EORTC confirmed that the baseline
HRQOL post-surgery but before other adjuvant therapies
was a prognostic factor for cancer survival [21].
In the current study, most glioma patients reported dif-
ficulties in emotional, social, cognitive, physical and role
functioning. Glioma had more burden effects on patients'
social and emotion functioning than other functioning.
All of these functioning scales were correlated with global
health status/QoL. Emotional dysfunction, such as
depression, anxiety, nervousness and irritability, were
common. Psychosocial intervention is needed for these
patients. The most common symptoms in these patients
were fatigue, pain, appetite loss, insomnia, and nausea/
vomiting. Fatigue was strongly related to all functioning,
pain, appetite loss and global health status/QoL. There-
fore, it is important for clinicians to realize and manage
fatigue. Compared with the study of Gustafsson et al. on
long-term LGG patients [6], pre-surgery glioma patients
in our study reported less cognitive impairment. PreviousCheng et al. BMC Cancer 2010, 10:305
http://www.biomedcentral.com/1471-2407/10/305
Page 6 of 8
studies have found that radiotherapy, antiepileptic drugs
and disease progression may cause cognitive impairment
[30-33]. However, we need further studies to document
the effects of therapies and diseases on HRQOL changes
in newly diagnosed glioma patients before any treatment
(including surgery), after treatment and during disease
progression in a single cohort. Therefore, ways of avoid-
ing cognitive impairment by the treatment should be
taken into consideration for glioma patients. Compared
with the reports from Osoba et al. [19,20] and Taphoorn
et al. [28,29], patients in our study only completed the
standard Chinese version of QLQ-C30 because the Chi-
nese version of BCM20 was unavailable, which could
have provided limited information on brain tumor-spe-
cific symptoms and functions. Patients in our study
included those with newly diagnosed glioma prior to first
surgery and recurrent glioma prior to re-operation. No
differences in scales or items in QLQ-C30 were found
between females and males or among patients with dif-
ferently located lesions, which disagrees with some other
reports [34,35]. It is difficult to compare these findings
with our results, given the different measures that were
used.
The MMSE is a well-validated and widely used screen-
ing test for dementia and cognitive impairment
[9,13,30,36-38]. It was unexpected that no differences
were found in any scale or item of QLQ-C30 (including
cognitive functioning scale) between patients classified as
having normal and abnormal cognition by MMSE. This
result is discordant with the finding that in a cohort with
various brain tumors, patients with normal cognition
reporting better physical and cognitive functioning, bet-
ter global health status/QoL, and worse fatigue and appe-
tite loss symptom levels (unpublished data), and that
deterioration in neurological function was accompanied
by significant deterioration in several QoL domains and
in global QoL [20]. We also found no difference in cogni-
tive functioning between patients older versus younger
than 50; however, there were more abnormally cognitive
patients as tested by MMSE among patients older than
50. These discrepancies may be attributed to poor valida-
tion of the cognitive functioning scale itself in the stan-
dard Chinese version of QLQ-C30 [18,39] and to the
possibility that more patients with cognitive dysfunction
according to MMSE had their QLQ-C30 completed by
their family members. Proxy-reported outcomes are
often discrepant with patient-reported outcomes [40].
Patients with KPS 80-100 presented with better func-
tioning and global health status/QoL and fewer fatigue,
pain, insomnia and appetite loss symptoms than those
with KPS less than 80. It is noteworthy that 69.2% of
patients had KPS of 80-100, while no difference was
shown in any scale or item of QLQ-C30 among these KPS
subgroups (KPS 80, 90 and 100; data not shown). Correla-
tional analysis showed that KPS was more strongly
related to physical functioning but more weakly related to
global health status/QoL. Additionally, most current
research excluded patients with KPS less than 70 [11,19].
Therefore, these data may suggested that KPS was an
inadequate surrogate for HRQOL. However, KPS may
still be useful in studies of HRQOL among patients who
are unable to provide reliable self-reported information.
There was a trend that patients with grade IV tumors
showed worse functioning (except for cognitive function-
ing), worse global health status/QoL, and more fatigue
and pain symptoms than patients with grade II and III
tumors. However, no statistically significant differences
existed between patients with grade II and III tumors. On
the other hand, Gustafsson et al. compared the HRQOL
outcomes in LGG (WHO grades I and II) patients with
those of HGG (WHO grades III and IV) patients
reported by Osoba et al. and found that the LGG patients
reported better physical, role and social functioning and
less fatigue and nausea, but they had more pain, with sim-
ilar cognitive and emotional functioning, global health
status/QoL and other symptoms [6]. The causes of this
disparity are unknown. It might be postulated that WHO
grade II patients showed more dysfunction and symp-
toms prior to surgery, which led them to early treatment
and thus a better prognosis and HRQOL after surgery
than WHO grade III patients. Another explanation could
be that patients had their poor prognoses of WHO grade
III or their better prognoses of WHO grade II confirmed
after surgery, and this knowledge may psychologically
affect their assessments of QoL. Patients with recurrent
glioma showed worse physical and social functioning and
global health status/QoL, as cancer recurrence may con-
tribute to HRQOL deterioration.
Our study has several limitations. First, we did not use
the BCM, as there was no available Chinese version.
Using the BCM would have allowed us to evaluate many
brain tumor-specific symptoms. Future studies should
include brain tumor-specific instruments. Second, larger
samples are required to validate our results. Third, the
study was cross-sectional and had a descriptive and cor-
relative design. Further research should follow these
patients and record their HRQOL changes during the
whole disease course.
Conclusions
In summary, this report provided the baseline HRQOL of
92 glioma patients prior to surgery in China. Most glioma
patients prior to surgery presented with emotional,
social, cognitive, physical and role impairments. Fatigue,
pain, appetite loss, insomnia, and nausea/vomiting were
common in these patients. The fatigue and pain symp-
toms and all scales of functioning were strongly corre-
lated with global health status/QoL. Fatigue was stronglyCheng et al. BMC Cancer 2010, 10:305
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related to all functioning scales, pain, appetite loss, and
global health status/QoL. Clinicians should help patients
deal with these symptoms and improve functioning. Old
age, worse performance status, WHO grade IV and
tumor recurrence had deleterious effects on HRQOL.
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related quality of life; KPS: Karnofsky Performance Status; L: left cerebral hemi-
sphere; LGG: low-grade gliomas; M: male; MMSE: Mini-Mental State Examina-
tion; MR: mean rank; N: normal cognition; NV: nausea/vomiting; OA:
oligoastrocytoma; OL: oligodendroglioma; PA: pain; QL: global health status;
QLQ-C30: Quality of Life Core Questionnaire 30; R: right cerebral hemisphere;
SF: social functioning; SL: insomnia; Sub: subtentorial tumor; Sup: supratento-
rial tumor.
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